Candidiasis Clinical Trial
Official title:
Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants < 750 Grams Birth
The most common etiology of infection-related death or neurodevelopmental impairment in
neonates with birthweight <750 g is invasive candidiasis. Over 70% of the premature neonates
who develop invasive candidiasis will die or suffer severe, permanent neurologic impairment.
Fluconazole has been commonly used off-label in the neonatal intensive care unit, but
definitive recommendations for its use in the nursery have been hampered by the limited
number of well-designed trials. In neonates weighing <750 g, appropriate dosing is not known,
definitive safety and long-term follow up trials have not been completed, and there have not
been well-powered trials conducted to establish the efficacy of the product using mortality
as part of the primary endpoint. Three recent proof-of-concept studies suggest that
fluconazole will be safe and effective, and a recently completed pharmacokinetic study is
providing data to give preliminary dosing guidance. The next logical step in drug development
is proposed by this research: to conduct a pivotal trial to determine the safety and efficacy
of fluconazole in premature neonates with 2-year neurodevelopmental follow-up assessment.
362 neonates, with a birthweight <750g, were randomized at 33 US centers, to twice weekly
fluconazole (6 mg/kg) or placebo for the first 6 weeks of life. The primary efficacy endpoint
will be Candida-free survival at study day 49. The research will establish definitive dosing,
safety, and efficacy of fluconazole; it will also provide critical information on the effects
of fluconazole on neurodevelopmental impairment and antifungal resistance.
Potential Impact:
Approximately 17,000 neonates are born <750 grams each year in the United States. Over 5000
will die or develop invasive Candida infections. Demonstrating safety and efficacy of
fluconazole in preterm neonates will improve the survivability and long term outcomes for
these neonates.
362 subjects were randomized to the study at 33 US sites. Final study visits of Month 18-22 corrected age long term follow up were completed. Study database is locked. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01982071 -
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
|
Phase 4 | |
| Completed |
NCT02391532 -
Effect of Probiotic Bacteria on Oral Candida in Frail Elderly
|
N/A | |
| Completed |
NCT01447407 -
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
|
Phase 1 | |
| Not yet recruiting |
NCT00889356 -
Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis
|
Phase 3 | |
| Completed |
NCT00105144 -
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
|
Phase 3 | |
| Completed |
NCT00163111 -
A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.
|
Phase 3 | |
| Completed |
NCT00138502 -
Funguria in Hospitalized Patients
|
||
| Not yet recruiting |
NCT04502277 -
Bioavailability of Flucanazole
|
Early Phase 1 | |
| Completed |
NCT03203551 -
Clinical and Laboratorial Evaluation of the Desinfection Solutions in Candida Species From Total Prostheses and Palate of Total Edentulous.
|
N/A | |
| Completed |
NCT05044156 -
Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women
|
||
| Completed |
NCT01322698 -
Staging Candidiasis in ICU Patients
|
N/A | |
| Terminated |
NCT01092832 -
A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
|
Phase 3 | |
| Terminated |
NCT00095316 -
Caspofungin Study for Fungal Infections in Adults in Critical Care Settings
|
Phase 3 | |
| Completed |
NCT04122560 -
Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration
|
Phase 4 | |
| Completed |
NCT02641717 -
Validity of Patient-Collected Wet Mounts
|
N/A | |
| Recruiting |
NCT01253954 -
A Multicenter Observational Study of Invasive Candida Infections Among ICU Patients in China
|
N/A | |
| Completed |
NCT00797420 -
Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers
|
Phase 1 | |
| Completed |
NCT00001937 -
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
|
Phase 3 | |
| Completed |
NCT02666716 -
Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients
|
||
| Terminated |
NCT00692783 -
Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility
|
N/A |